Free Trial

Heatwurx (PCSA) Competitors

Heatwurx logo
$0.41 +0.01 (+3.46%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$0.39 -0.02 (-4.10%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PCSA vs. COEP, CRVO, HOWL, OKYO, JATT, ABVC, PMVP, PRLD, GANX, and BYSI

Should you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include Coeptis Therapeutics (COEP), CervoMed (CRVO), Werewolf Therapeutics (HOWL), OKYO Pharma (OKYO), JATT Acquisition (JATT), ABVC BioPharma (ABVC), PMV Pharmaceuticals (PMVP), Prelude Therapeutics (PRLD), Gain Therapeutics (GANX), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

Heatwurx vs. Its Competitors

Heatwurx (NASDAQ:PCSA) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 2.4% of Heatwurx shares are held by insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Heatwurx has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500.

Heatwurx presently has a consensus target price of $1.00, indicating a potential upside of 144.02%. Given Heatwurx's stronger consensus rating and higher possible upside, research analysts clearly believe Heatwurx is more favorable than Coeptis Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heatwurx
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Coeptis Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Coeptis Therapeutics' return on equity of -201.73% beat Heatwurx's return on equity.

Company Net Margins Return on Equity Return on Assets
HeatwurxN/A -342.36% -243.48%
Coeptis Therapeutics N/A -201.73%-108.46%

Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HeatwurxN/AN/A-$11.85M-$2.32-0.18
Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.64

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Heatwurx. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 1 mentions for Heatwurx. Heatwurx's average media sentiment score of 0.95 beat Coeptis Therapeutics' score of 0.90 indicating that Heatwurx is being referred to more favorably in the media.

Company Overall Sentiment
Heatwurx Positive
Coeptis Therapeutics Positive

Summary

Heatwurx beats Coeptis Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PCSA vs. The Competition

MetricHeatwurxMED IndustryMedical SectorNASDAQ Exchange
Market Cap$19.94M$2.96B$6.12B$10.45B
Dividend YieldN/A57.77%5.73%4.78%
P/E Ratio-0.1822.7985.3827.36
Price / SalesN/A778.16602.69196.46
Price / CashN/A172.6337.4661.86
Price / Book0.895.5112.516.81
Net Income-$11.85M$33.06M$3.32B$276.80M
7 Day Performance4.35%0.23%0.60%0.42%
1 Month Performance104.39%14.73%10.53%7.86%
1 Year Performance-68.95%-1.42%74.30%41.24%

Heatwurx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCSA
Heatwurx
3.27 of 5 stars
$0.41
+3.5%
$1.00
+144.0%
-67.0%$19.94MN/A-0.1820Gap Up
COEP
Coeptis Therapeutics
1.3035 of 5 stars
$15.55
-1.0%
N/A+280.3%$75.68MN/A-2.682
CRVO
CervoMed
3.5545 of 5 stars
$8.01
-1.7%
$19.29
+140.8%
-42.2%$75.41M$9.74M-3.074Analyst Downgrade
HOWL
Werewolf Therapeutics
3.4945 of 5 stars
$1.63
flat
$8.00
+390.8%
-12.4%$74.54M$1.88M-0.9940News Coverage
OKYO
OKYO Pharma
2.8554 of 5 stars
$2.00
+2.4%
$7.00
+250.0%
+102.9%$73.49MN/A0.007Gap Up
JATT
JATT Acquisition
N/A$4.15
-8.0%
N/A-13.9%$71.59MN/A0.003Gap Down
High Trading Volume
ABVC
ABVC BioPharma
0.8802 of 5 stars
$2.96
-2.6%
N/A+394.0%$71.57M$510K-17.4130
PMVP
PMV Pharmaceuticals
3.0336 of 5 stars
$1.32
-2.2%
$5.50
+316.7%
-3.4%$71.54MN/A-0.8450Analyst Forecast
PRLD
Prelude Therapeutics
3.4539 of 5 stars
$1.25
-0.8%
$4.00
+220.0%
-28.8%$71.32M$7M-0.76120
GANX
Gain Therapeutics
3.1249 of 5 stars
$1.90
-3.6%
$7.86
+313.5%
-22.1%$70.82M$50K-3.0220Analyst Forecast
Gap Up
BYSI
BeyondSpring
N/A$1.71
-1.7%
N/A-33.7%$70.18M$1.75M0.0080News Coverage
High Trading Volume

Related Companies and Tools


This page (NASDAQ:PCSA) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners